Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biomidwest entities : Eli lilly and company save search
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
Published: 2023-12-12 (Crawled : 22:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: 0.0%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: 0.21%
H: 1.18%
C: 0.43%
breast life cancer pharmaceuticals results
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: 0.29%
H: 1.26%
C: 0.87%
publication pharmaceuticals trial results
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 15:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: 0.49%
H: 0.83%
C: -2.14%
breast symposium presentation cancer pharmaceuticals
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
Published: 2023-11-02 (Crawled : 12:00) - biospace.com/
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -0.16%
H: 1.5%
C: 1.19%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 4.42%
H: 0.0%
C: 0.0%
sales business financial growth
Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -1.43%
pharmaceuticals results
Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology
Published: 2023-09-28 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: 0.22%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.28%
H: 0.07%
C: -1.25%
grant technology
The Top 12 Biopharma Companies Hiring Now
Published: 2023-09-13 (Crawled : 14:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
companies biopharma
Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.48%
C: -0.19%
LGND | $72.61 -7.94% -8.62% 130K
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: -3.7%
conference breast presentation cancer pharmaceuticals research
COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer
Published: 2023-07-19 (Crawled : 13:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.04%
H: 0.8%
C: 0.48%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 7.98%
H: 0.0%
C: 0.0%
GBIO | $2.775 -6.88% -7.39% 200K
|
Health Technology
|
| O: -0.19%
H: 9.21%
C: -1.73%
pharmaceuticals
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Published: 2023-04-27 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
obesity diabetes tirzepatide
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
BWV | $0.1802 5.44% 530K
|
|
| O: 1.51%
H: 2.73%
C: -2.73%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: 0.92%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: 2.91%
H: 16.04%
C: 13.21%
entadfi water acquisition blue
Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement
Published: 2023-04-13 (Crawled : 16:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.79%
C: 0.68%
announcement conference financial results
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 23:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.14%
H: 1.0%
C: 0.93%
research meeting association cancer
Lilly to Participate in Cowen's 43rd Annual Health Care Conference
Published: 2023-02-21 (Crawled : 15:20) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.38%
H: 1.4%
C: 0.11%
care conference health
Lilly to Participate in SVB Securities Global Biopharma Conference
Published: 2023-02-07 (Crawled : 20:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.48%
H: 1.46%
C: 1.08%
biopharma global conference
Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement
Published: 2022-10-19 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.11%
C: -1.78%
announcement conference financial
Eli Lilly's Phase III Atopic Dermatitis Drug Touts Significant Skin Clearance
Published: 2022-06-07 (Crawled : 15:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
clearance drug dermatitis skin
Fresenius Kabi Introduces New Generic for the Treatment of Non-Squamous Non-Small Cell Lung Cancer
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.84%
H: 0.0%
C: 0.0%
treatment cancer
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
Published: 2022-05-12 (Crawled : 11:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.09%
H: 3.06%
C: 2.99%
VERU | $1.42 22.41% 18.31% 7M
|
Health Technology
|
| O: -24.43%
H: 26.44%
C: 23.7%
covid-19 sabizabulin authorization emergency use authorization
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Published: 2022-03-16 (Crawled : 14:00) - biospace.com/
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
jardiance pos kidney trial disease positive
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.